Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitric oxide/endothelin balance after nephron reduction

S Aiello1, G Remuzzi, M Noris

  • 1Mario Negri Institute for Pharmacological Research, Ospedali Riuniti, Bergamo, Italy.

Kidney International. Supplement
|April 29, 1998
PubMed
Summary

Renal disease progression involves reduced nitric oxide (NO) and increased endothelin-1 (ET-1). Restoring NO or blocking ET-1 pathways may slow kidney disease and improve function.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.

The Cochrane database of systematic reviews·2004
Same author

Genetics of rare diseases of the kidney: learning from mouse models.

Cytogenetic and genome research·2004
Same author

Nephrotoxic aspects of cyclosporine.

Transplantation proceedings·2004
Same author

Proteinuria and its consequences in renal disease.

Acta paediatrica (Oslo, Norway : 1992). Supplement·2004
Same author

Pharmacological and clinical profile of valsartan.

Drugs of today (Barcelona, Spain : 1998)·2004
Same author

[Thrombotic microangiopathy].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia·2003

Area of Science:

  • Nephrology
  • Physiology
  • Biochemistry

Background:

  • Nitric oxide (NO) plays crucial roles in vasodilation and immune response.
  • Progressive nephropathies are linked to complex hemodynamic and hemostatic disorders.
  • The nitric oxide (NO) synthetic pathway's role in renal disease progression is under investigation.

Purpose of the Study:

  • To investigate the role of nitric oxide (NO) and endothelin-1 (ET-1) in renal mass reduction (RMR) induced kidney disease.
  • To explore therapeutic strategies targeting NO and ET-1 pathways in experimental renal disease.

Main Methods:

  • Utilized a rat model of renal mass reduction (RMR).
  • Assessed renal nitric oxide (NO) generation and inducible NO synthase (iNOS) expression.
  • Measured endothelin-1 (ET-1) synthesis and its mRNA levels.
  • Administered L-arginine, NO-releasing compounds, and an ETA receptor antagonist.

Main Results:

  • Rats with RMR showed decreased renal NO generation and impaired iNOS content, worsening with time.
  • Renal ET-1 synthesis progressively increased in RMR rats.
  • Administration of L-arginine, NO donors, or an ETA receptor antagonist ameliorated proteinuria, slowed disease progression, and improved survival.
  • ETA receptor antagonism corrected impaired renal NO synthesis, suggesting ET-1's inhibitory effect on NO production.

Conclusions:

  • Abnormalities in renal NO and ET-1 synthetic pathways play complementary roles in promoting hemodynamic and functional alterations in progressive nephropathies.
  • Modulating NO and ET-1 pathways offers potential therapeutic strategies for managing kidney disease progression.

Related Experiment Videos